Market Opportunity - Breast reconstruction represents a $1.5 billion market[13, 19, 21, 22, 25] - Biologics account for 65% of reconstruction spending in the US[25, 27] - Approximately 160,000 breasts are reconstructed annually after mastectomy[27] - Biologic mesh is utilized in over 90% of reconstruction cases[27] Unmet Needs and Solutions - One in three patients experience serious complications following breast reconstruction[16, 21, 22, 28] - One in seven patients undergoing breast reconstruction face infection[21, 22, 28] - Implant loss occurs in up to 21% of breast reconstruction cases[28] - The company's NXT-41x aims to address these complications with a drug-eluting bioenvelope[36] Technology and Development - The company's technology platform has been validated, with a previous product monetized for $88 million[12, 13] - The company is developing NXT-41x, combining an optimal biologic matrix with Rifampin and Minocycline for sustained antibiotic release[36] - The company anticipates launching NXT-41x in the first half of 2027[44]
Elutia (NasdaqCM:ELUT) Earnings Call Presentation